Last reviewed · How we verify
Aripiprazole, Solian, Olanzapine, Seroquel, Risperidone
Aripiprazole, marketed by Korea Otsuka Pharmaceutical Co., Ltd., is a well-established antipsychotic in the psychiatric market with a key composition patent expiring in 2028. The drug's primary strength lies in its broad spectrum of indications and strong market presence. The primary risk is the potential increase in generic competition following the patent expiry in 2028.
At a glance
| Generic name | Aripiprazole, Solian, Olanzapine, Seroquel, Risperidone |
|---|---|
| Sponsor | Korea Otsuka Pharmaceutical Co., Ltd. |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- An Observational Drug Utilization Study of Asenapine in the United Kingdom (P08308)
- Pharmacovigilance in Gerontopsychiatric Patients (PHASE3)
- Clinical Trial to Evaluate the Efficacy of Treatment vs Discontinuation in a First Episode of Non-affective Psychosis (PHASE3)
- SWitching to Abilify Trial (SWAT) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: